Ovarian cancer: The prognostic value of the serum half-life of CA125 during induction chemotherapy

M. E. L. van der Burg; F. B. Lammes; W. L. J. van Putten; G. Stoter

doi:10.1016/0090-8258(88)90244-2

Ovarian cancer: The prognostic value of the serum half-life of CA125 during induction chemotherapy

M. E. L. van der Burg^*
, F. B. Lammes
, W. L. J. van Putten
, G. Stoter

^*Corresponding author for this work

Erasmus University Rotterdam
Amsterdam UMC - University of Amsterdam

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Eighty-five patients with epithelial ovarian cancer were studied to assess the prognostic value of the prechemotherapy serum concentration of CA125 and its half-life during induction therapy. The endpoints of the analysis were progression rate and time to progression. The prechemotherapy CA125 level had no prognostic value (P = 0.36) if the patients were stratified for tumor size. The half-life of CA125, however, was an independent prognostic variable (P = 0.01). Patients with a half-life of 20 days and more had a 3.2 times higher progression rate and a significantly shorter median time to progression of only 11 months, as compared to 43 months for patients with a half-life of less than 20 days. © 1988.

Original language	English
Pages (from-to)	307-312
Journal	Gynecologic oncology
Volume	30
Issue number	3
DOIs	https://doi.org/10.1016/0090-8258(88)90244-2
Publication status	Published - 1988
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/0090-8258(88)90244-2

Cite this

@article{4e831c58036c456eb54cd3127ed87c48,

title = "Ovarian cancer: The prognostic value of the serum half-life of CA125 during induction chemotherapy",

abstract = "Eighty-five patients with epithelial ovarian cancer were studied to assess the prognostic value of the prechemotherapy serum concentration of CA125 and its half-life during induction therapy. The endpoints of the analysis were progression rate and time to progression. The prechemotherapy CA125 level had no prognostic value (P = 0.36) if the patients were stratified for tumor size. The half-life of CA125, however, was an independent prognostic variable (P = 0.01). Patients with a half-life of 20 days and more had a 3.2 times higher progression rate and a significantly shorter median time to progression of only 11 months, as compared to 43 months for patients with a half-life of less than 20 days. {\textcopyright} 1988.",

author = "\{van der Burg\}, \{M. E. L.\} and Lammes, \{F. B.\} and \{van Putten\}, \{W. L. J.\} and G. Stoter",

year = "1988",

doi = "10.1016/0090-8258(88)90244-2",

language = "English",

volume = "30",

pages = "307--312",

journal = "Gynecologic oncology",

issn = "0090-8258",

publisher = "Academic Press Inc.",

number = "3",

}

TY - JOUR

T1 - Ovarian cancer

T2 - The prognostic value of the serum half-life of CA125 during induction chemotherapy

AU - van der Burg, M. E. L.

AU - Lammes, F. B.

AU - van Putten, W. L. J.

AU - Stoter, G.

PY - 1988

Y1 - 1988

N2 - Eighty-five patients with epithelial ovarian cancer were studied to assess the prognostic value of the prechemotherapy serum concentration of CA125 and its half-life during induction therapy. The endpoints of the analysis were progression rate and time to progression. The prechemotherapy CA125 level had no prognostic value (P = 0.36) if the patients were stratified for tumor size. The half-life of CA125, however, was an independent prognostic variable (P = 0.01). Patients with a half-life of 20 days and more had a 3.2 times higher progression rate and a significantly shorter median time to progression of only 11 months, as compared to 43 months for patients with a half-life of less than 20 days. © 1988.

AB - Eighty-five patients with epithelial ovarian cancer were studied to assess the prognostic value of the prechemotherapy serum concentration of CA125 and its half-life during induction therapy. The endpoints of the analysis were progression rate and time to progression. The prechemotherapy CA125 level had no prognostic value (P = 0.36) if the patients were stratified for tumor size. The half-life of CA125, however, was an independent prognostic variable (P = 0.01). Patients with a half-life of 20 days and more had a 3.2 times higher progression rate and a significantly shorter median time to progression of only 11 months, as compared to 43 months for patients with a half-life of less than 20 days. © 1988.

UR - https://www.scopus.com/pages/publications/0023729656

UR - https://www.ncbi.nlm.nih.gov/pubmed/3164697

U2 - 10.1016/0090-8258(88)90244-2

DO - 10.1016/0090-8258(88)90244-2

M3 - Article

C2 - 3164697

SN - 0090-8258

VL - 30

SP - 307

EP - 312

JO - Gynecologic oncology

JF - Gynecologic oncology

IS - 3

ER -

Ovarian cancer: The prognostic value of the serum half-life of CA125 during induction chemotherapy

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this